NCT02605811

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Radiation Versus Temozolomide in Preventing Brain Metastases in Limited Stage Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 426 (estimated)
• Sponsor: Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

Detailed description

We'd like to investigate the 2-year incidence rate of brain metastases in completed or partial remission limited small cell lung cancer patients who received temozolomide only for 12 months or 25-30Gy prophylactic cranial radiotherapy in preventing brain metastases.

Conditions

• Small Cell Lung Cancer
• Metastatic Carcinoma

Interventions

Type	Name	Description
DRUG	temozolomide
RADIATION	prophylaxis cranial radiotherapy	2

Timeline

• Start date: 2015-09-01
• Primary completion: 2019-12-01
• Completion: 2021-12-01
• First posted: 2015-11-16
• Last updated: 2019-03-28

Locations

1 site across 1 country: China